Dao, Pascal; Smith, Nikaia; Tomkiewicz-Raulet, Celine; Yen-Pon, Expedite; Camacho-Artacho, Marta; Lietha, Daniel; Herbeuval, Jean-Phillipe; Coumoul, Xavier; Garbay, Christiane; Chen, Huixiong published the artcile< Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity>, Application In Synthesis of 30095-98-8, the main research area is imidazo triazine preparation focal adhesion kinase inhibitor antitumor activity.
A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines. We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines, e.g., I. Importantly, these new compounds displayed 10-7-10-8 M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymic activity. Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK. Apoptosis anal. in U87-MG and HCT-116 cell lines suggested that these compounds delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth. Further investigation demonstrated that these compounds strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.
Journal of Medicinal Chemistry published new progress about Antitumor agents. 30095-98-8 belongs to class esters-buliding-blocks, and the molecular formula is C9H9NO4, Application In Synthesis of 30095-98-8.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics